Upcoming Presentations in the Medical Field
Opus Genetics, Inc. (NASDAQ: IRD), a pioneering force in the clinical biopharmaceutical industry, is preparing to unveil promising advancements in gene therapies dedicated to inherited retinal diseases. With its innovative spirit, Opus is eager to share exceptional clinical results from its notable programs at prominent medical and industry conferences scheduled for October.
Key Highlights from Conference Participation
At the forefront of these presentations are the encouraging clinical results from both the IRD gene therapy and the Phentolamine Ophthalmic Solution 0.75% (POS) programs. The opportunity to engage with the gene therapy sector, ophthalmology circles, and investors at these distinguished meetings will spotlight the company's ongoing advancements.
Cell and Gene Meeting on the Mesa
Presentation Title: Transformative Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
Content Discussed: Attendees will delve into a three-month pediatric and 18-month adult clinical data report highlighting insights from the Phase 1/2 trial of OPGx-LCA5, particularly focusing on patients affected by Leber congenital amaurosis type 5.
Date/Time: Monday, October 6, 2025, from 9:15 to 9:30 AM MT
Presenter: George Magrath, M.D., Chief Executive Officer
Location: Arizona Biltmore, Phoenix
Fierce Biotech Week
Fireside Chat: Investing with Intention – Exploring the Foundations of Opus Genetics
Date/Time: Wednesday, October 8, 2025, from 12:15 to 12:45 PM ET
Speakers: Ben Yerxa, Ph.D., President, and Christy Shaffer, Ph.D., General Partner
Location: Encore Boston Harbor Hotel, Boston
American Academy of Optometry Annual Meeting 2025
Poster Presentation: LYNX-2: A Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution for subjects experiencing decreased visual acuity post keratorefractive surgery.
Date: October 9, 2025, from 4:30 to 6:30 PM ET
Presenter: Marc Bloomenstein, O.D.
Location: Halls B2/C, Thomas M. Menino Convention & Exhibition Center, Boston
Eyecelerator @ American Academy of Ophthalmology (AAO)
Presentation Title: Continuing Developments in Gene Therapies for Rare Inherited Retinal Diseases
Content Overview: Presentation of three-month pediatric and 18-month adult clinical data from the OPGx-LCA5 Phase 1/2 trial.
Session Date/Time: Thursday, October 16, 2025, from 1:15 to 2:45 PM ET
Presenter: Sally Tucker, Ph.D., Senior Vice President of Clinical Development
Location: Orange County Convention Center, Orlando
About Opus Genetics
Founded with a commitment to transform the landscape of gene therapy, Opus Genetics specializes in developing groundbreaking therapeutic approaches targeting inherited retinal diseases (IRDs). This strategic focus has led the company to develop AAV-based gene therapies designed to combat conditions like Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Currently, its lead candidates, OPGx-LCA5 and OPGx-BEST1, are under rigorous investigation, ensuring that the company remains at the cutting edge of innovation in the treatment landscape.
Additionally, Opus is advancing the Phentolamine Ophthalmic Solution 0.75%, a partnered therapy successfully approved in one indication and being evaluated in two Phase 3 trials aimed at addressing presbyopia and managing visual disturbances in low-light and nighttime conditions. This dedication to research and development fortifies Opus' position in the biopharmaceutical field, based in Research Triangle Park.
For further information on Opus Genetics and their innovative solutions, visit www.opusgtx.com.
Frequently Asked Questions
1. What is Opus Genetics known for?
Opus Genetics is recognized for its development of gene therapies targeting inherited retinal diseases and other ophthalmic disorders.
2. What are OPGx-LCA5 and OPGx-BEST1?
These are Opus Genetics' lead gene therapy candidates targeting specific inherited retinal conditions.
3. When is Opus Genetics presenting at the upcoming conferences?
Opus will present at various events in October 2025, including the Cell and Gene Meeting and American Academy of Optometry Annual Meeting.
4. Who are the speakers at the Fierce Biotech Week?
Ben Yerxa, Ph.D., and Christy Shaffer, Ph.D., will be the speakers during the panel discussion at this event.
5. What is the aim of the Phentolamine Ophthalmic Solution?
The solution is aimed at treating presbyopia and managing low-light visual disturbances, currently in Phase 3 studies.
